

CARDIOVASCULAR SYSTEMS INC

FORM 8-K (Current report filing)

Filed 11/26/13 for the Period Ending 11/26/13

Address	651 CAMPUS DRIVE ST PAUL, MN 55112
Telephone	651-259-1600
CIK	0001180145
Symbol	CSII
SIC Code	3841 - Surgical and Medical Instruments and Apparatus
Industry	Medical Equipment & Supplies
Sector	Healthcare
Fiscal Year	06/30

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 26, 2013

Cardiovascular Systems, Inc.
(Exact name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-52082
(Commission
File Number)

41-1698056
(IRS Employer
Identification No.)

651 Campus Drive
St. Paul, Minnesota 55112-3495
(Address of Principal Executive Offices and Zip Code)

(651) 259-1600
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

On November 26, 2013, Cardiovascular Systems, Inc. (the “Company”) issued a press release announcing that it had closed the offering of an aggregate of 3,000,000 shares of Company common stock, including 391,304 shares of common stock sold pursuant to the full exercise by the underwriters of their option to purchase additional shares. The press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.**(d) Exhibits**

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated November 26, 2013

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 26, 2013

CARDIOVASCULAR SYSTEMS, INC.

By: /s/ Laurence L. Betterley

Laurence L. Betterley
Chief Financial Officer

INDEX TO EXHIBITS

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated November 26, 2013



CARDIOVASCULAR SYSTEMS ANNOUNCES CLOSING OF COMMON STOCK OFFERING AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

St. Paul, Minn. – November 26, 2013 – Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) today announced the closing of its underwritten registered public offering of an aggregate of 3,000,000 shares of its common stock, including 391,304 shares of common stock sold pursuant to the full exercise by the underwriters of their option to purchase additional shares. All of the shares were sold at a price to the public of \$30.00 per share. The aggregate net proceeds to the company from this offering are approximately \$84.5 million, after deducting underwriting discounts and commissions and estimated offering expenses.

BofA Merrill Lynch acted as the sole book-running manager of the offering. Leerink Swann acted as joint lead manager. William Blair, JMP Securities, Dougherty & Company, Feltl & Company and Wunderlich Securities acted as co-managers.

The shares of common stock were sold pursuant to the company's effective shelf registration statement.

The offering of these securities was made only by means of a prospectus and related prospectus supplement, copies of which may be obtained by visiting EDGAR on the Securities and Exchange Commission's website at <http://www.sec.gov>. Alternatively, copies of the final prospectus supplement and base prospectus related to the offering may be obtained by contacting BofA Merrill Lynch at 222 Broadway, New York, NY 10038, Attention: Prospectus Department or by e-mailing dg.prospectus_requests@baml.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of CSI, and there will not be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in August 2007. To date, over 125,000 of CSI's devices have been sold to leading institutions across the United States. In October 2013, the company received FDA approval for the use of the Diamondback Orbital Atherectomy System in coronary arteries.

Contacts:

For Cardiovascular Systems, Inc.

Investor Relations
(651) 259-2800
investorrelations@csi360.com

PadillaCRT
Marian Briggs
(612) 455-1742
marian.briggs@padillacrt.com

Matt Sullivan
(612) 455-1709
matt.sullivan@padillacrt.com